Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-Escalation Surgery Following Immunotherapy for Locally Advanced HNSCC
NCT07320690Phase 3Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jan 2026
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Overall Survival at 3 years. Planned start Jan 2026; status: not yet recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07320690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320690.